Market Trends of Thrombosis Drugs Industry
Deep Vein Thrombosis (DVT) Segment is Expected to Register a Significant Growth during the Forecast Period
Deep vein thrombosis (DVT) is a blood clot in one of the large, deep veins that returns blood from the leg and rarely in the arm or heart. The segment's growth is driven by the increasing prevalence of chronic deep vein thrombosis and product launches by key market players. Increasing focus on developing low-cost drugs and a large patient pool further contribute to the growth of the thrombosis drugs market.
According to a study published in Nature Journal in October 2023, approximately 1,220,000 total cases of VTE occur in the United States annually. The incidence of VTE in Europe and the United States is estimated to be ~1–2 per 1,000 person-years but varies widely by age, sex, race, and medical conditions. In Asia, the rates of VTE are thought to be lower than in Europe and the USA. For instance, the incidence of VTE in South Korea was estimated to be 0.2 per 1,000 person-years. Thus, the growing prevalence of deep vein thrombosis is expected to drive the segment's growth over the forecast period.
Market players are focusing on introducing innovative products, further adding to the market growth. For instance, in February 2024, Bayer initiated proof-of-concept trials for a novel therapy aimed at patients suffering from deep vein thrombosis (DVT). Differing from existing medications, Bayer's German team has launched the SIRIUS phase 2 trial. This trial focuses on evaluating the efficacy of their anti-alpha2 antiplasmin (anti-α2ap) antibody, BAY3018250, in DVT patients. DVT manifests when blood clots develop in the deep veins, predominantly in the legs. DVT is often associated with old age, which is also expected to enhance the segment growth.
Thus, all factors above, such as the high prevalence of DVT and increasing product launches, are expected to boost the market's growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to hold a significant share of the market owing to the prevalence of cardiovascular diseases and obesity, the upsurge in demand for progressive treatment options, the early adoption of new technologies, and an increase in the elderly population. Besides, the presence of a diverse patient pool and the increase in participation of domestic and foreign companies in the campaign in these regions is also projected to contribute to the market growth.
The growing burden of thrombotic diseases is expected to contribute in the growth of the market over the forecast period. For instance, as per the data updated by CDC in May 2024, up to 900,000 people in the United States are affected by venous thromboembolism (VTE, a blood clot), each year. Thus, a high burden is anticipated to increase demand for thrombosis drugs, thereby boosting the market growth.
Moreover, according to the data updated by the Canadian Institute for Health Information in July 2022, it was estimated that about 2.4 million Canadians had heart disease in the current year. Thus, with the increasing burden of cardiovascular diseases across the country, the studied market is expected to witness strong growth, as it would lead to increased usage of thrombosis drugs for treatment.
Thus, all aforementioned factors such as the high prevalence of cardiovascular diseases and the growing geriatric population are expected to boost the market growth over the forecast period.
